Article Impact Level: HIGH Data Quality: STRONG Summary of Science Advances, 11(31), eadu3700. https://doi.org/10.1126/sciadv.adu3700 Dr. Hsiao-Yun Lin et al.
Points
- Researchers have discovered that the antidiabetic drug metformin exerts its effects through a previously unrecognized neural mechanism involving the small guanosine triphosphate (GTP) binding protein Rap1 in the brain.
- The ventromedial hypothalamic nucleus was identified as the crucial site of action, where metformin-induced inhibition of Rap1 is essential for effectively lowering blood glucose levels.
- Genetically modified mice lacking Rap1 in the forebrain were resistant to metformin’s antidiabetic effects, while direct brain administration of the drug lowered hyperglycemia at minuscule doses.
- Metformin was shown to activate a specific subset of SF1 neurons within the ventromedial hypothalamus, an action that is entirely dependent on the presence of the Rap1 protein.
- These findings highlight a brain-centric pathway for a widely used medication and suggest new therapeutic strategies for diabetes that could directly target this specific neural circuit.
Summary
For over 60 years, the precise mechanism of metformin, the first-line therapy for type 2 diabetes, has been debated, with prevailing theories focusing on peripheral actions in the liver and gut. New research now identifies a critical, previously unrecognized central mechanism. The study posits that metformin’s clinically relevant antidiabetic effects are mediated through a neural pathway involving the small guanosine triphosphatase, Ras-related protein 1 (Rap1), within the ventromedial hypothalamic nucleus (VMH) of the brain. This central action appears to be highly sensitive, as direct central administration of metformin in mice reduced hyperglycemia at doses thousands of times smaller than typical oral doses.
To validate this hypothesis, researchers utilized mice with forebrain-specific Rap1 knockout. When subjected to a high-fat diet to induce a diabetic state, these mice exhibited resistance to the glycemic-lowering effects of low-dose metformin. At the same time, their sensitivity to other antidiabetic agents, such as insulin and GLP-1 agonists, remained intact. Conversely, forced activation of brain Rap1 in wild-type mice elevated glycemia and completely abolished metformin’s therapeutic effect. These loss-of-function and gain-of-function studies demonstrate that VMH Rap1 is indispensable for the drug’s action.
The investigation further identified a specific subset of neurons in the VMH, known as SF1 neurons, that are activated by metformin. Electrophysiological recordings from brain slices confirmed that metformin increases the activity of these neurons; however, this effect was absent in mice lacking Rap1, underscoring the protein’s essential role in the drug’s activation of the neural circuit. These findings establish the brain’s VMH Rap1 pathway as a principal mediator of metformin’s antidiabetic effects, opening new avenues for developing therapies that can directly target this highly sensitive central mechanism for glucose regulation.
Link to the article: https://www.science.org/doi/10.1126/sciadv.adu3700
References Lin, H.-Y., Lu, W., He, Y., Fu, Y., Kaneko, K., Huang, P., De La Puente-Gomez, A. B., Wang, C., Yang, Y., Li, F., Xu, Y., & Fukuda, M. (2025). Low-dose metformin requires brain Rap1 for its antidiabetic action. Science Advances, 11(31), eadu3700. https://doi.org/10.1126/sciadv.adu3700
